Downloads
Abstract
Objectives: To evaluate the outcomes of high dose chemotherapy (HDC) and autologous peripheral blood stem cell transplantation (PBSCT) in patients with advanced stage or relapsed ovarian cancer.
Method: Uncontrolled clinical trial.
Subject: 11 patients with advanved stage or relapsed ovarian cancer that were treated by HDC in support of autologous PBSCT, and followed up from October 2012 to May 2018.
Results: Severe bone marrow failure was the most common complication after high dose chemotherapy in patients with advanced stage or relapsed ovarian cancer. Stem cell transplantation dose was 4.70 ± 1.62 CD34+ cells x 106/kg. The mean time of recovery was 7.5 ± 0.8 (6 - 9) days for white blood cells and 9.5 ± 2.1 (7 – 13) days for platelets. The estimated rates of 3- year OS and DFS were 72.7% and 63.6%, respectively.
Conclusion: High dose chemotherapy with the support of autologous PBSCT in the treatment of patients with advanced stage or relapsed ovarian cancer could be safe and effective.
References
Bensinger WI (2004), High-dose Preparatory Regimens, Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4th Edition, 316-332.
Castonguay V, Wilson MK, Diaz-Padilla ID, Wang L, Oza AM (2015), Estimation of Expectedness: Predictive Accuracy of Standard Therapy Outcomes in Randomized Phase 3 Studies in Epithelial Ovarian Cancer, Cancer, 121: 413-422.
Chan S, Griffin M, Stewarty J, Gregoryzx K, Hughesk A, et al (2007) Modern Chemothera- py Management of Recurrent Ovarian Cancer: A Multicentre Study, Clinical Oncology 19: 129-134.
Chase DM, Gibson SJ, Monk BJ, Tewari KS (2013), Updates on Anti-Cancer Therapy in Ovarian Cancer, Chemotherapy, 2(1): 109-117.
Chobanian N, Dietrich CS (2008), Ovarian cancer, Surg Clin North Am, 88(2): 285-299.
Doroshow JH, Synold T (2007), Pharmacologic Basis for High-Dose Chemotherapy, Thomas’ Hematopoietic Cell Transplantation, Third Edition, 130-157.
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R (2015) Optimal primary surgical treatment for advanced epithelial ovarian cancer (Review), Cochrane Database of Systematic Reviews, CD007565.
Legros M, Dauplat J, Fleury J et al (1997) High-Dose Chemotherapy With Hematopoietic Rescue in Patients With Stage III to IV Ovarian Cancer: Long-Term Results, J Clin Oncol 15: 1302-1308.
Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, et al (2007), Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First- Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, 25: 4187-4193.
Salerno MG, Ferrandina G, Greggi S, Pier- elli L, Menichella G, et al (2001), High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results, Bone Marrow Transplantation, 27: 1017- 1025.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital